Literature DB >> 26286944

Middle East respiratory syndrome (MERS) in Asia: lessons gleaned from the South Korean outbreak.

Poh Lian Lim1.   

Abstract

Entities:  

Keywords:  Asia; Emerging infections; Middle East respiratory syndrome coronavirus; Outbreaks; South Korea; Travel

Mesh:

Year:  2015        PMID: 26286944      PMCID: PMC7107261          DOI: 10.1093/trstmh/trv064

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


× No keyword cloud information.
The first case of Middle East respiratory syndrome coronavirus (MERS-CoV) was reported in 2012.[1] Over the past 3 years, sporadic travel-associated importations occurred to countries in Europe, North Africa and Asia, and cases continued to smoulder in Saudi Arabia,[2] but the risk assessment by most experts was that MERS-CoV was a low risk for causing a pandemic.[3,4] With a reproductive number (Ro) estimated at close to 1.0 by some experts, MERS-CoV was considered unlikely to propagate enough to cause a large outbreak.[5] However, before 2014, a similar argument could have been made for the likelihood of a large outbreak of Ebola—in over four decades, Ebola had never caused more than several hundred cases at worst. It appears that the disclaimer made for financial investments applies equally well to emerging infections—past experience is no guarantee of future performance. On 4 May 2015, a 68-year-old Korean man returned from travel in the Middle East. He became symptomatic on 11 May and sought medical attention on 12 May. He was admitted and discharged, then re-admitted at a second hospital where the diagnosis of MERS-CoV infection was confirmed on 20 May.[6] In the week before diagnosis, this index case was not suspected to have MERS-CoV and, therefore, his caregivers did not use appropriate isolation precautions and personal protective equipment. As a result of this critical lapse, South Korea experienced a large outbreak and is now the country with the second largest number of MERS-CoV cases in the world, after Saudi Arabia. As of 23 July 2015, this outbreak stands at 186 cases, with 36 deaths and a case fatality rate of 19%;[7] South Korea appears to be on track to declare the outbreak over by August 2015 after completing two incubation periods without new cases. Over 16 000 individuals had to be quarantined for potential exposure and over 30 healthcare facilities had to undergo investigations for possible MERS-CoV transmission. This outbreak caused considerable anxiety in Asia because one of the second generation cases travelled to China (Guangzhou and Hong Kong), requiring strenuous contact tracing efforts of fellow airplane passengers and others exposed to the patient. As a result, countries around the region issued travel warnings, stepped up screening efforts and activated thermal scanners for incoming passengers from South Korea. This outbreak took a substantial toll on South Korea, economically and politically, in addition to the human impact. The question still remains: why did this MERS-CoV outbreak occur in South Korea when the preceding 3 years had seen multiple other importations that did not result in an outbreak, even in less developed countries? A WHO team, led by Dr Keiji Fukuda, was dispatched to investigate this outbreak.[8] Initial concerns, about viral mutation resulting in a more transmissible pathogen were not borne out by viral sequencing data. The concept of ‘super-spreaders’ was again mooted. For severe acute respiratory syndrome (SARS) veterans watching this outbreak unfold, a sense of déjà vu prevailed. These events reinforced five key observations and learning points (Box 1). It only takes one: a single imported case can spark an outbreak. Travel matters: in our globalised world, diseases are just a plane flight away. Hospitals are a risk for amplifying outbreaks; therefore, manage that risk well. The myth of the ‘super-spreader’. To stop outbreaks, we need effective, rapid and coordinated approaches. With over a billion individuals travelling annually, the risk of emerging infections crossing borders is a reality that needs to be managed with calibrated, sensible approaches. South Korea's experience illustrates the ongoing need for a high level of vigilance. To control emerging infections for which no preventive vaccines or proven specific therapies are available, classical outbreak control measures are still required—transmission can be terminated by isolating infectious cases and quarantining exposed individuals during the incubation period. Suspect cases must be cared for with appropriate precautions in order to protect hospital staff, visitors and other patients, all of whom would inadvertently become vectors for spread, if infected. Super-spreaders are a myth, rather than a mystery. It is more appropriate to speak of super-spreading incidents, which occur because an individual is not suspected to have infection. The number of secondary cases increases proportionate to the duration that an individual remains out of isolation after symptoms develop. Medical procedures that aerosolise viral particles further increase the likelihood of super-spreading incidents. Decisive action is required to stop outbreaks. The 2014–2015 Ebola outbreak in West Africa demonstrates what can happen if rapid, coordinated action is not taken early enough, and has resulted in calls for a global health emergency workforce. This role is currently filled by WHO and the Global Outbreak Alert and Response Network (GOARN), but they need more resources to strengthen outbreak response and build capacity. This outbreak also underscores one other critical component to managing outbreaks—communications at the speed of trust. Unlike SARS in 2003, MERS is occurring in a different milieu. In 2015, social media must be reckoned with. Clear, consistent and accurate communications becomes ever more important to maintain credibility for governments and health authorities.[9] South Korea's early decision to withhold the names of MERS-affected hospitals caused more anxiety, loss of confidence and proved, ultimately, futile. In the aftermath of South Korea's outbreak, preparedness efforts in Asia were ramped up in many countries in Asia. In Singapore, health advisories for travellers to and from Korea and border screening with thermal scanners were implemented, along with the usual circulars to all healthcare facilities and doctors to increase vigilance for travel-related importations. Tan Tock Seng Hospital and the Communicable Disease Centre are the designated facilities in Singapore for outbreak management, including Ebola, MERS-CoV and avian influenza. Over the past 3 years, our hospital has evaluated over 300 patients who either walked in themselves or were referred by a doctor for possible MERS-CoV infection. Our Emergency Department doctors balance the risk of missing a case with the challenges of admitting reluctant patients to isolation rooms (which are a finite resource). For front-line clinicians without the luxury of hindsight, knowledge of the case definitions (pneumonia plus travel exposure) is balanced by awareness that the spectrum of disease includes mild infection, clinical presentations may evolve and upper respiratory samples may not detect infection, especially early in the course of illness.[10] What happened in South Korea could happen in any country in Asia—our task is to stop the outbreak before it happens. These emerging infection outbreaks reinforce the need to stay vigilant and to invest in capacity building to detect and respond quickly to outbreaks with effective, decisive actions. Global health security requires this commitment from every country because outbreaks teach us that we are only as strong as our weakest link.
  6 in total

1.  Taking stock of the first 133 MERS coronavirus cases globally--Is the epidemic changing?

Authors:  P M Penttinen; K Kaasik-Aaslav; A Friaux; A Donachie; B Sudre; A J Amato-Gauci; Z A Memish; D Coulombier
Journal:  Euro Surveill       Date:  2013-09-26

2.  Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015.

Authors:  H Y Park; E J Lee; Y W Ryu; Y Kim; H Kim; H Lee; S J Yi
Journal:  Euro Surveill       Date:  2015-06-25

3.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

4.  Middle East Respiratory Syndrome coronavirus (MERS CoV): Update 2013.

Authors:  Poh Lian Lim; Tau Hong Lee; Emily K Rowe
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

5.  Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk.

Authors:  Romulus Breban; Julien Riou; Arnaud Fontanet
Journal:  Lancet       Date:  2013-07-05       Impact factor: 79.321

6.  Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus.

Authors:  Matthew Cotten; Simon J Watson; Alimuddin I Zumla; Hatem Q Makhdoom; Anne L Palser; Swee Hoe Ong; Abdullah A Al Rabeeah; Rafat F Alhakeem; Abdullah Assiri; Jaffar A Al-Tawfiq; Ali Albarrak; Mazin Barry; Atef Shibl; Fahad A Alrabiah; Sami Hajjar; Hanan H Balkhy; Hesham Flemban; Andrew Rambaut; Paul Kellam; Ziad A Memish
Journal:  mBio       Date:  2014-02-18       Impact factor: 7.867

  6 in total
  9 in total

Review 1.  MERS coronavirus: diagnostics, epidemiology and transmission.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Virol J       Date:  2015-12-22       Impact factor: 4.099

2.  Modeling the Transmission of Middle East Respirator Syndrome Corona Virus in the Republic of Korea.

Authors:  Zhi-Qiang Xia; Juan Zhang; Ya-Kui Xue; Gui-Quan Sun; Zhen Jin
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

3.  Zero Transmission of Middle East Respiratory Syndrome: Lessons Learned From Thailand.

Authors:  Surasak Wiboonchutikul; Weerawat Manosuthi; Chariya Sangsajja
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

4.  Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design.

Authors:  Jeong Yoon Lee; Sojung Bae; Jinjong Myoung
Journal:  J Microbiol       Date:  2019-08-27       Impact factor: 3.422

5.  Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications.

Authors:  K H Kim; T E Tandi; J W Choi; J M Moon; M S Kim
Journal:  J Hosp Infect       Date:  2016-10-14       Impact factor: 3.926

6.  Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran.

Authors:  Afshin Moniri; Majid Marjani; Payam Tabarsi; Davood Yadegarynia; Seyed Alireza Nadji
Journal:  Tanaffos       Date:  2015

7.  Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.

Authors:  A Bleibtreu; S Jaureguiberry; N Houhou; D Boutolleau; H Guillot; D Vallois; J C Lucet; J Robert; B Mourvillier; J Delemazure; M Jaspard; F X Lescure; C Rioux; E Caumes; Y Yazdanapanah
Journal:  BMC Infect Dis       Date:  2018-07-16       Impact factor: 3.090

8.  Influenza not MERS CoV among returning Hajj and Umrah pilgrims with respiratory illness, Kashmir, north India, 2014-15.

Authors:  Parvaiz A Koul; Hyder Mir; Siddhartha Saha; Mandeep S Chadha; Varsha Potdar; Marc-Alain Widdowson; Renu B Lal; Anand Krishnan
Journal:  Travel Med Infect Dis       Date:  2016-12-06       Impact factor: 6.211

9.  Middle East respiratory syndrome coronavirus intermittent positive cases: Implications for infection control.

Authors:  Sarah H Alfaraj; Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Am J Infect Control       Date:  2018-10-21       Impact factor: 2.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.